HC Wainwright Has Bullish Estimate for ACTU FY2025 Earnings

Actuate Therapeutics, Inc. (NASDAQ:ACTU) – HC Wainwright boosted their FY2025 earnings estimates for shares of Actuate Therapeutics in a research report issued on Wednesday, November 19th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($1.00) for the year, up from their previous forecast of ($1.02). HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. HC Wainwright also issued estimates for Actuate Therapeutics’ Q4 2025 earnings at ($0.24) EPS, Q1 2026 earnings at ($0.23) EPS, Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.25) EPS, Q4 2026 earnings at ($0.26) EPS, FY2026 earnings at ($0.97) EPS, FY2027 earnings at ($1.05) EPS and FY2028 earnings at ($1.04) EPS.

Other research analysts have also recently issued research reports about the company. Wall Street Zen upgraded Actuate Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 20th. B. Riley started coverage on Actuate Therapeutics in a report on Tuesday, August 26th. They set a “buy” rating and a $20.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Actuate Therapeutics in a research report on Wednesday. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.33.

Actuate Therapeutics Stock Performance

ACTU stock opened at $6.31 on Friday. The firm has a 50 day moving average price of $6.84 and a 200-day moving average price of $7.64. Actuate Therapeutics has a 52-week low of $5.47 and a 52-week high of $11.99. The firm has a market capitalization of $146.66 million, a price-to-earnings ratio of -7.25 and a beta of -0.23.

Actuate Therapeutics (NASDAQ:ACTU) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.02.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Sfmg LLC lifted its holdings in shares of Actuate Therapeutics by 32.3% during the second quarter. Sfmg LLC now owns 14,550 shares of the company’s stock valued at $89,000 after purchasing an additional 3,550 shares in the last quarter. Chicago Partners Investment Group LLC purchased a new position in Actuate Therapeutics in the 1st quarter worth about $70,000. Goldman Sachs Group Inc. raised its position in Actuate Therapeutics by 98.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 22,358 shares of the company’s stock worth $151,000 after buying an additional 11,105 shares during the last quarter. Bank of America Corp DE lifted its stake in Actuate Therapeutics by 61,068.0% during the 2nd quarter. Bank of America Corp DE now owns 15,292 shares of the company’s stock valued at $93,000 after acquiring an additional 15,267 shares during the period. Finally, Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Actuate Therapeutics by 492.6% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 18,518 shares of the company’s stock valued at $113,000 after acquiring an additional 15,393 shares during the last quarter.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.